Last reviewed · How we verify
Regulatory Post Marketing Surveillance Study of NovoRapid for New Drug Re-examination
This study is conducted in Asia. The aim of this study is to observe the safety and efficacy of insulin aspart (NovoRapid®) administered via vial and three different devices.
Details
| Lead sponsor | Novo Nordisk A/S |
|---|---|
| Status | COMPLETED |
| Enrolment | 1239 |
| Start date | 2005-01 |
| Completion | 2006-06 |
Conditions
- Diabetes
- Diabetes Mellitus, Type 1
- Diabetes Mellitus, Type 2
Interventions
- insulin aspart
Primary outcomes
- Change in weight
Countries
South Korea